CG Oncology (CGON) Projected to Post Quarterly Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is projected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $0.0730 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Performance

Shares of NASDAQ:CGON traded down $0.90 during trading hours on Tuesday, hitting $41.00. 19,436 shares of the company’s stock traded hands, compared to its average volume of 986,637. CG Oncology has a 52 week low of $14.80 and a 52 week high of $45.56. The company’s fifty day simple moving average is $37.55 and its two-hundred day simple moving average is $29.87. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -23.22 and a beta of 1.32.

Insider Transactions at CG Oncology

In other news, Director Brian Guan-Chyun Liu purchased 1,515,151 shares of CG Oncology stock in a transaction on Thursday, September 11th. The stock was purchased at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the transaction, the director directly owned 1,515,151 shares in the company, valued at $49,999,983. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Hong Fang Song sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $27.80, for a total value of $2,780,000.00. Following the transaction, the director directly owned 2,903,931 shares of the company’s stock, valued at approximately $80,729,281.80. This trade represents a 3.33% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 174,359 shares of company stock worth $5,511,784.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. boosted its stake in shares of CG Oncology by 5.3% during the second quarter. Invesco Ltd. now owns 29,231 shares of the company’s stock valued at $760,000 after purchasing an additional 1,477 shares in the last quarter. Federated Hermes Inc. increased its stake in CG Oncology by 20.0% in the 2nd quarter. Federated Hermes Inc. now owns 10,200 shares of the company’s stock worth $265,000 after acquiring an additional 1,700 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of CG Oncology by 27.2% during the 2nd quarter. New York State Common Retirement Fund now owns 17,796 shares of the company’s stock valued at $463,000 after purchasing an additional 3,800 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in CG Oncology by 159.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after acquiring an additional 4,288 shares during the period. Finally, PDT Partners LLC lifted its stake in shares of CG Oncology by 6.5% in the 2nd quarter. PDT Partners LLC now owns 72,143 shares of the company’s stock valued at $1,876,000 after purchasing an additional 4,426 shares during the period. Institutional investors own 26.56% of the company’s stock.

Analyst Ratings Changes

CGON has been the subject of several research reports. Royal Bank Of Canada decreased their price target on shares of CG Oncology from $68.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, July 16th. JPMorgan Chase & Co. lifted their price target on shares of CG Oncology from $41.00 to $47.00 and gave the company an “overweight” rating in a research report on Friday, September 26th. Morgan Stanley lifted their price target on shares of CG Oncology from $56.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, September 17th. Guggenheim started coverage on shares of CG Oncology in a research report on Tuesday, October 7th. They set a “buy” rating and a $90.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of CG Oncology in a research report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $58.70.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.